论文部分内容阅读
作者选用两种现行的口服肠道活菌苗伤寒杆菌Ty21a和霍乱弧菌CVD103-HgR进行联合,并对其免疫原性和安全性进行评价.作者将330名志愿者随机分成两组,安慰剂组于1、3和5天各口服1剂一次含5×10~8CFU的热灭活大肠杆菌;联合菌苗组的免疫程序则为:第1天口服第1剂含2×10~9～6×10~9CFU的Ty21a和2×10~8～6×10~8CFU的CVD103-HgR的联合菌苗,第3和第5天各口服1剂2×10~9～6×10~9CFU的单价伤寒Ty21a菌苗.每次服苗后30分钟观察有无恶心、呕吐、腹泻、腹痛、发热、头痛、疲劳和皮疹等不良反应.于服苗前和服苗
The authors selected two current oral enteric bacilli Salmonella typhi Ty21a and Vibrio cholerae CVD103-HgR were combined, and its immunogenicity and safety were evaluated 330 volunteers were randomly divided into two groups, placebo Groups were treated with 5 × 10 ~ 8CFU heat-inactivated Escherichia coli once a day for 1, 3 and 5 days. The immunization procedure of combination vaccine group was as follows: Day 1 oral first dose containing 2 × 10 ~ 9 ~ 6 × 10 ~ 9CFU of Ty21a and 2 × 10 ~ 8 ~ 6 × 10 ~ 8CFU of CVD103-HgR combined vaccine, on the 3rd and 5th days of each oral administration of 2 × 10 ~ 9 ~ 6 × 10 ~ 9CFU Monovalent Typhimurium Ty21a vaccine.Every 30 minutes after taking vaccine to observe whether there is nausea, vomiting, diarrhea, abdominal pain, fever, headache, fatigue and rash and other adverse reactions.